In our study, ERCC1 expression provided both prognostic and predictive information in patients with completely resected bladder cancer. Among patients with transitional cell carcinoma of the bladder treated with cystectomy, high tumoral expression of ERCC1 correlated with longer survival in patients without adjuvant chemotherapy and was associated with shorter survival in those with adjuvant chemotherapy. A statistically significant interaction between ERCC1 expression and adjuvant chemotherapy indicated potential benefits of adjuvant chemotherapy in patients with ERCC1-negative tumors.. To date, the role of adjuvant chemotherapy for bladder cancer has been controversial, with no Level 1 evidence supporting adjuvant chemotherapy. In fact, the available data have not demonstrated a clear benefit of adjuvant chemotherapy. Despite mounting evidence favoring neoadjuvant chemotherapy [1-3], physicians are reluctant to adopt its practice as evidenced by only 1.2% of patients with stage III bladder ...
Giuliani, F; Marco, A D.; Casazza, A M.; and Savi, G, "Combination chemotherapy and surgical adjuvant chemotherapy on ms-2 sarcoma and lung metastases in mice." (1979). Subject Strain Bibliography 1979. 165 ...
TY - JOUR. T1 - Surgery and adjuvant chemotherapy use among veterans with colon cancer. T2 - Insights from a California study. AU - Hynes, Denise M.. AU - Tarlov, Elizabeth. AU - Durazo-Arvizu, Ramon. AU - Perrin, Ruth. AU - Zhang, Qiuying. AU - Weichle, Thomas. AU - Ferreira, M. Rosario. AU - Lee, Todd. AU - Benson, Al B.. AU - Bhoopalam, Nirmala. AU - Bennett, Charles L.. PY - 2010/5/20. Y1 - 2010/5/20. N2 - Purpose: US veterans have been shown to be a vulnerable population with high cancer rates, and cancer care quality in Veterans Affairs (VA) hospitals is the focus of a congressionally mandated review. We examined rates of surgery and chemotherapy use among veterans with colon cancer at VA and non-VA facilities in California to gain insight into factors associated with quality of cancer care. Methods: A retrospective cohort of incident colon cancer patients from the California Cancer Registry, who were ≥ 66 years old and eligible to use VA and Medicare between 1999 and 2001, were observed ...
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellul
A new study conducted by ASCO in collaboration with the American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) and published in the Journal of Clinical Oncology1 found that patients who have to travel farther to appointments are less likely to receive adjuvant chemotherapy, regardless of whether or not they are insured.. Evidence-based treatment guidelines recommend the use of adjuvant chemotherapy in many cancer patients within 90 days after surgery. But studies show that in many cases, patients do not receive it.. To explore the role geographic access to care plays, researchers compared patients travel distance, insurance status, and an areas density of oncologists to the likelihood patients received adjuvant chemotherapy within 90 days of surgery for colon cancer. The data used in the study captured about 70% of newly diagnosed cancer cases in the United States.. Of 34,694 patients in the study cohort, three-quarters (75.7%) received adjuvant chemotherapy ...
Operation is the only curative treatment for gastric cancer patients. However, the rate of recurrence is high up to 60%. The 5 years overall survival of patient at stage IIIb or more advanced stage is still poor and approximately 8-28%. Adjuvant chemotherapy is critical for improving efficacy further. Unfortunately, the optimal adjuvant regimen is not identified yet. The standard adjuvant treatments of American and European patients are not accepted widely in Asia area because of different operation procedure and patients tolerability. Results of two critical trials indicated that S-1 alone as Japanese standard adjuvant chemotherapy could not improve the survival of stage IIIb advanced stage gastric cancer patients while the Korean standard regimen XELOX could. This implied that the more intensive chemotherapy must be used for the patients with higher risk of relapse. The proportion of the stage IIIb-IIIc Chinese gastric cancer patients is much larger than that of Japan and Korean. However, no ...
With very few exceptions, initial therapy for colon cancer is adequate surgical resection. Subsequent surgical and pathologic staging will dictate the need for adjuvant therapy. Currently, Stage I colon cancer patients enjoy a high cure rate after surgery alone (,80%), and there is no evidence that these patients will benefit from any adjuvant therapy. Large randomized clinical trials have been more interested in Stage II and Stage III colon cancer patients whose cure rate can be as low as 30% after surgery alone. Early chemotherapy trials for colon cancer used the chemotherapeutic agents available at the time. Eventually, fluorinated pyrimidines (5-Fluorouracil or 5-FU) were shown to have activity against metastatic colorectal cancer. This finding led to several trials evaluating 5-FU as adjuvant therapy for high risk patients after surgery (Stage II and III colon cancer). In 1988, Buyse and colleagues(4) published a meta-analysis of all randomized controlled trials of adjuvant therapy with ...
Barrett-Lee, P., Ellis, P., Bliss, J., TACT (Taxotere as Adjuvant Chemotherapy Trial) Management Group (includes John Yarnold) (2002) Duration of adjuvant chemotherapy; Anthracyclines, taxanes and novel agents - More or less. JOURNAL OF CLINICAL ONCOLOGY, 14 (4). pp. 263-266. ISSN 0732-183X ...
BACKGROUND: Although the benefit from adjuvant chemotherapy has been established clearly in patients with Stage III colon carcinoma, the degree to which elderly patients with colon carcinoma can tolerate such therapy generally has remained unknown. METHODS: The authors reviewed all patients in their Tumor Registry with Stage II and Stage III adenocarcinoma of the colon who underwent potentially curative resection for their disease at the Geisinger Medical Center between January 1990 and September 2000. One hundred twenty patients underwent complete resection of their colon carcinoma and received 5-fluorouracil-based (5-FU) adjuvant chemotherapy. RESULTS: The 5-year disease free survival rate for patients age | or =65 years (Group A) was 70% compared with 56% for patients age | 65 years (Group B) (P = 0.085). The 5-year overall survival rate for patients in Group B was 77% compared with 62% for the patients in Group A (P = 0.143). In a Cox regression model, age was not a predictor of disease free
Among the total 1,036 breast cancer cases, 190 (18.3%) were cases of TNBC. NCCN guidelines and the St. Gallen consensus conference recommend adjuvant chemotherapy for TNBC [26], although a specific regimen for such adjuvant treatment has yet to be presented. In the 190 TNBC cases of the present study, patients undergoing surgery plus adjuvant therapy had a more favorable prognosis than those receiving surgery alone, only among those with Stage II disease, suggesting that adjuvant therapy is indeed useful for TNBC patients as the NCCN recommends, and is most relevant at Stage II. In the adjuvant therapy group, both univariate and multivariate analysis showed no significant difference in prognosis between the anthracyclin-based regimen and 5FU-based regimen, although patients with the former regimen showed a trend-level improvement in prognosis over those with the latter. Larger studies might be necessary to clarify the prognoses of anthracyclin-based regimen and 5FU-based regimen.. Since reliable ...
Ethnic and socioeconomic inequities in use of breast cancer adjuvant therapy are well documented in many countries including the USA, and are known to contribute to lower breast cancer survival among minority ethnic and socioeconomically deprived women. We investigated ethnic and socioeconomic inequities in use of adjuvant radiotherapy and chemotherapy in a cohort of women with invasive breast cancer in New Zealand. All women with newly diagnosed invasive breast cancer during 1999-2012 were identified from the Waikato Breast Cancer Register. Rates of chemotherapy use and radiotherapy use were assessed in women who were deemed to be eligible for chemotherapy (n = 1212) and radiotherapy (n = 1708) based on guidelines. Factors associated with use of chemotherapy and radiation therapy were analysed in univariate and multivariate regression models, adjusting for covariates. Overall, rates of chemotherapy and radiotherapy use were 69% (n = 836) and 87.3% (n = 1491), respectively. In the multivariate model,
Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.. chemotherapy: Given within 10 weeks after surgery.. ...
Objectives: The 21-Gene Recurrence Score (RS) assay helps guide adjuvant chemotherapy use for patients with breast cancer, and is predicted to reduce overall chemotherapy use. Little is known about recent patterns of testing in the Medicare program and the impact of testing on chemotherapy use as a function of patient age. Materials and Methods: We conducted a national claims-based study of Medicare beneficiaries age ≥66 years. We assessed trends in assay use (using multivariable regression), adjuvant chemotherapy use, and associated expenditures, for all patients and for two age strata: age 66-74 years and 75-94 years. Geographic variations in assay adoption and regional-level correlation between assay and chemotherapy use were measured. Results: We identified 132,222 women who underwent breast surgery from 2008-2011. Assay use increased from 9.0% to 17.2% from 2008-2011 (p|.001), but chemotherapy use remained stable at 12.5% (p=.49). In younger patients, assay use increased from 14.3% to 23.7% (p|
Background: The potential benefit of adjuvant chemotherapy in patients with Stage IA triple negative breast cancer (TNBC) has not been defined. In general, patients with T1a and T1b lesions have not been included in adjuvant chemotherapy trials and the inclusion of T1c tumors has been limited. In this study using National Cancer Data Base (NCDB) we investigated the actual use of adjuvant chemotherapy in Stage IA TNBC patients relative to tumor size (T1a, T1b, T1c) and report their survival outcomes.. Patients and Methods: Using NCDB we evaluated a cohort of 13,065 women with TNBC diagnosed between 2010-2012 who had American Joint Committee on Cancer Stage IA (node-negative with pathological T1a, T1b or T1c) tumors. Overall survival (OS) was the primary outcome variable. Based on the tumor size, patients were stratified on receipt of adjuvant chemotherapy or not. Patients were also stratified according to receipt of adjuvant radiation, radiation with boost, or none. Other adjusted variables ...
A prospective validation study of a 21-gene expression assay showed that treatment with endocrine therapy alone in women with hormone receptor-positive, HER2-negative breast cancer who had a low recurrence risk score resulted in low risk of recurrence. All patients included in the study were eligible for adjuvant chemotherapy on the basis of current guidelines, as reported in The New England Journal of Medicine by Joseph A. Sparano, MD, of Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, and colleagues.1. Study Details. Between April 2006 and October 2010, the trial enrolled 10,253 women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6-1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for receiving adjuvant chemotherapy.. A 21-gene reverse-transcriptase polymerase chain reaction assay was performed on ...
This study is investigating low dose versus standard dose capecitabine adjuvant chemotherapy for chinese elderly patients with stage II/III colorectal
Background: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. Methods: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defined the adjusted odds ratio (aOR) and associated 95% CI of receipt of adjuvant chemotherapy. Among patients receiving chemotherapy, multivariable logistic regression assessed the odds of treatment with multiagent chemotherapy. Results: Among 18,463 patients, 11,288 (61.1%) received any adjuvant chemotherapy. Sociodemographic factors inversely associated with receipt of any adjuvant chemotherapy included uninsured status (aOR, 0.61; 95% CI, 0.50-0.74), Medicaid insurance (aOR, 0.66; 95% CI, ...
The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B wa...
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
... ,Patients: 5.10 underwent total resection and left breast sentinel, pathology showed 3 infiltrating ductal carcinoma, tumor diameter 1.5cm, n
Although there has been some progress in chemotherapy for metastatic gastric cancer, no standard regimen of adjuvant chemotherapy is available, and many
Based on the results of 3 adjuvant trials (MOSAIC,20 NSABP-C-07,21 and XELOXA22), oxaliplatin-based combinational chemotherapy is considered the standard of care for patients with stage III colon cancer, offering a 4% overall survival (OS) benefit over 5FU/LV at 6 years. However, the additional benefit of oxaliplatin in older patients appears to be attenuated. Subset analyses of MOSAIC and NSABP C-07 trials showed no significant benefit in OS with the addition of oxaliplatin in patients age 70 or older (MOSAIC mortality hazard ratio [HR] = 1.10; 95% confidence interval [CI], 0.73-1.65; for NSABP-C-07, HR = 1.32; 95% CI, 1.03-1.70).20,21 In contrast, a subgroup analysis of XELOXA, a study that evaluated the use of oral capecitabine in combination with oxaliplatin versus bolus 5FU/LV, the benefits of disease-free survival (DFS) were maintained regardless of age, but no significant OS benefit was shown.22 In an analysis using the ACCENT23 database of 2575 patients age ≥70 years using ...
Overuse of adjuvant chemotherapy in colon adenocarcinoma patients aged less than 50 years does not greatly improve their survival
Similarly claims that chemotherapy have produced increased percentage 5-year survival for other cancers, such as cancer of the large bowel1, could be attributed to poor methodology because none of these cancers exhibited a divergence between incidence and mortality rate curves over time5.. Ulrich Abel reviewed the evidence for the efficacy of chemotherapy for invasive epithelial cancer6, the types of cancer for which chemotherapy is most commonly used. He concluded that there was some evidence from randomised trials that chemotherapy increased survival only for small-cell lung cancer. Yet even here the gain in survival was measured in weeks or months.. Adjuvant chemotherapy for breast cancer It is widely claimed that adjuvant chemotherapy extends survival with late-stage breast cancer. For example, in a letter in the Sydney Morning Herald of 22 November 1996 Professor Allan Langlands claimed that the results of a meta-analysis of more than 100 trials of adjuvant systemic therapy in many ...
Sometimes a treatment may be started at a lower dose or the dose needs to be changed during treatment. There may also be times when your treatment is delayed. This can happen if your doctor thinks you are likely to have severe side effects, if you get severe side effects, if your blood counts are affected and causing delays in treatment, or if you are finding it hard to cope with the treatment. This is called a dose reduction, dose change or treatment delay. Your doctor will explain if you need any changes or delays to your treatment and the reason why. ...
BACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0 ...
Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos and Earl, Helena M.. (2015) A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1). 306. ISSN 1741-7015 ...
ROCHESTER, Minnesota-Fluorouracil (5-FU)-based chemotherapy after surgery can be given safely to selected elderly patients with stage II/III colon cancer, and these patients derive the same benefits from the treatment as do their younger counterparts, according to results of a pooled analysis of seven clinical trials. 1
TY - JOUR. T1 - Estimating regimen-specific costs of chemotherapy for breast cancer. T2 - Observational cohort study. AU - Giordano, Sharon H.. AU - Niu, Jiangong. AU - Chavez-MacGregor, Mariana. AU - Zhao, Hui. AU - Zorzi, Daria. AU - Shih, Ya Chen Tina. AU - Smith, Benjamin D.. AU - Shen, Chan. PY - 2016/11/15. Y1 - 2016/11/15. N2 - BACKGROUND: One goal for high-quality patient care is communicating treatment costs to patients, yet cost information can be elusive. This is especially relevant for breast cancer care, for which numerous guideline-concordant adjuvant chemotherapy regimens exist. The objective of the current study was to generate cost estimates for such regimens from payers and patients perspectives in a large, insured US population. METHODS: Adult women who had incident breast cancer diagnosed between 2008 and 2012 (from the MarketScan database), had no secondary malignancy within 1 year of diagnosis, and received chemotherapy within 3 months of diagnosis were included (n = ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
目的:分析胃癌根治术后辅助治疗的疗效和副作用。方法:2005年1月至2012年9月在本院接受综合治疗的患者,男性94例,女性62例,平均年龄58.2岁(23~84岁,中位58岁)。所有病例均为手术病理证实为胃癌,按AJCC分期第7版标准,IA期7例,IB期7例,IIA期6例,IIB期19例,IIIA25例,IIIB期34例,IIIC期44例,IV期12例,不详2例。156例均采用根治性切除。12例术后未行任何化疗,142例术后接受各种方案的化疗,其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案,66例采用铂类 + 氟尿嘧啶类两药方案,9例采用口服替吉奥或卡培他滨单药化疗,1例仅采用铂类 + 氟尿嘧啶类腹腔灌注,2例化疗方案不详。有28例接受术后放疗。结果:中位随访36.5月。3年总生存率为53.5%,3年局部控制率为82.0%,3年无远处转移率53.8%。单因素分析显示T分期(T1-3或T4)
This study assessed the efficacy of adjuvant capecitabine in patients with liver cancer also receiving routine supportive care. The primary measure of interest
Even if the cancer is advanced and it is not possible to remove it, some surgical techniques may still have a place to ease symptoms. For example, a blockage may be eased by using laser surgery, by inserting a rigid stent (tube), or by stretching the oesophagus (dilatation), which allows food and drink to pass through the blockage to the stomach.. Chemotherapy. Chemotherapy is a treatment of cancer by using anti-cancer medicines which kill cancer cells, or stop them from multiplying. Following surgery you may be given a course of chemotherapy. This aims to kill any cancer cells which may have spread away from the primary tumour. When chemotherapy is used after surgery it is called adjuvant chemotherapy. In some cases chemotherapy is given before surgery, to shrink a large tumour so that surgery is more likely to be successful. This is called neoadjuvant chemotherapy. Radiotherapy. Radiotherapy is a treatment which uses high-energy beams of radiation which are focused on cancerous tissue. This ...
1)To determine whether the addition of erlotinib to gemcitabine adjuvant chemotherapy improves survival as compared to gemcitabine alone following R0 or R1 resection of head of pacreas adenocarcionoma (including adenocarcinoma of the head, neck, and uncinate process ...
Adjuvant therapy begins after surgical removal of the tumour. You will decide with your oncologist on adjuvant treatment such as chemotherapy or radiation.
Cancer Therapy Advisor provides obsteticians and gynecologists with the latest information to correctly diagnose obgyn conditions, recommend procedures and guides. Visit often for updates and new information.
What is primary chemotherapy, me-adjuvant chemotherapy, and adjuvant chemotherapy? Primary chemotherapy refers to chemotherapy administered as the prim
Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer
A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.
The BCIRG 001 study was a pivotal trial showing the benefit of incorporating a taxane into adjuvant breast cancer polychemotherapy (10). However, the substitution of docetaxel for fluorouracil increased toxicities, and not all patients remained disease free. Consequently, it was our objective to determine which patients are most likely to benefit from adjuvant therapy with docetaxel. The identification of such molecular predictive factors is, however, complex because most markers correlated with outcome most frequently are prognostic rather than predictive (i.e., related to prognosis only in the setting of treatment with a specific intervention; refs. 11, 21), and the mechanistic determinants of docetaxel response are poorly understood. Evaluation within the context of a randomized trial, such as BCIRG 001, is required to distinguish between the prognostic and the predictive value of a given biomarker.. In this immunohistochemical study, Ki-67 protein was found to be independently associated ...
Adjuvant therapy in the past 10 years has gone from experimental to clinical practice for women who are premenopausal. For the postmenopausal and the elderly patient the treatment for some is still...
thirdtimer66 - Patient: Lung Cancer > Lymphoma Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: over 7 years ago, Male, Age: 73
Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin ...
Anthracycline-based chemotherapies are effective and are widely used as the main postoperative adjuvant chemotherapy for patients with early-stage breast cancer (1-3). However, those treatments are accompanied by a high incidence of nausea and vomiting (4,5), severely compromising the patients QOL. The use of 5HT3 receptor antagonists has become commonplace in recent years, enabling a certain level of control of these symptoms. However, fatigue and decreased physical QOL remain challenging issues in breast cancer patients receiving postoperative adjuvant chemotherapy, and methods for alleviating these symptoms are needed (9). In our earlier single-group open study, in which LEM was coadministered to breast cancer patients who were treated with the FEC75 regimen, the QOL-ACD (24) was used to evaluate the effect of LEM on the patients QOL. The results indicated that coadministration of LEM was effective in improving the patients physical scale in response to the FEC75 regimen. LEM is a BRM ...
TY - JOUR. T1 - Completion of therapy by medicare patients with stage III colon cancer. AU - Dobie, Sharon A.. AU - Baldwin, Laura Mae. AU - Dominitz, Jason A.. AU - Matthews, Barbara. AU - Billingsley, Kevin. AU - Barlow, William. PY - 2006/5/3. Y1 - 2006/5/3. N2 - Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer ...
The multiinstitutional osteosarcoma study (MIOS), a randomized trial of adjuvant therapy for osteosarcoma with a concurrent control group, registered 113 patients from June 1982 to August 1984. Preliminary analysis of the study indicated a significant event-free survival advantage favoring immediate adjuvant chemotherapy, (P less than .001). For patients treated with surgery alone or with surgery and adjuvant chemotherapy, the lungs were involved in more than 80% of the relapses. Patients relapsing after surgery alone tended to relapse earlier (P less than .01), had more pulmonary nodules (P less than .01), and had more frequent bilateral pulmonary involvement (P less than .01) than those treated with immediate postsurgical adjuvant chemotherapy. However, patients relapsing after treatment with surgery alone experienced a significantly longer interval to further disease progression (P less than .01) and improved survival after relapse (P = .01) when compared with patients who relapsed after ...
The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no surv
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
In this prospective study, we showed that MMR status in colorectal cancer may predict adjuvant chemotherapy response. Thus while in general, patients with stage II or III disease who received 5-FU based adjuvant chemotherapy had a better overall survival and disease free survival, this benefit was found only in patients with MMR competent tumours. Patients with MMR deficient tumours did not have a better survival or disease free survival when they received 5-FU adjuvant chemotherapy. The results remained unchanged when we stratified according to TNM stage. Conversely, when we analysed the efficacy of treatment received according to MMR status, we found that patients with MMR deficient tumours who did not receive adjuvant chemotherapy had a slightly better survival and disease free survival than patients with MMR competent tumours, even though the analysis failed to reach statistical significance.. Several studies have evaluated the benefit of adjuvant chemotherapy according to MMR status of ...